VTYX News and Press, Ventyx Biosciences Inc. From 03/20/23

2023-03-20 08:57:38 ET Summary Dan Loeb's 13F portfolio value increased from $5.53B to $5.97B this quarter. The number of positions decreased from 61 to 44. Third Point added American International Group, Microsoft, and International Flavors & Fragrances while dropping Cano He...

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today an...

ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Depos...

Dan Loeb's Third Point LLC  confirmed its new stake in American International Group ( NYSE: AIG ) with 5.1M shares and bulked up on its stake in Bath & Body Works ( NYSE: BBWI ), increasing it to ~13.8M shares from ~8.14M shares, during Q4 2022, according to its latest 13...

Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete ...

Summary Ventyx Biosciences, Inc. has three interesting molecules in inflammatory diseases. Each is in a different pathway validated by approved drugs. The company's value lies in differentiating its molecules from these competing drugs. Ventyx Biosciences, Inc. ( VTYX ...

Summary Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD. The latest clinical trials on Ensifentrine u...

ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, toda...

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, toda...

Ventyx Biosciences ( NASDAQ: VTYX ) has filed for a $150M mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds to invest in a variety of interest-bearing instruments. ...